The Best Treatments to Use After Checkpoint Inhibition in Melanoma

Grant McArthur, MBBS, PhD

H&O  Which patients with melanoma are candidates for checkpoint inhibition? GM  All patients with unresectable metastatic melanoma—stage IV and unresectable stage III disease—are candidates for checkpoint […]

Antibody-Drug Conjugates in Breast Cancer

Aditya Bardia, MD, MPH

  H&O  What are antibody-drug conjugates (ADCs)? AB  ADCs are drugs that contain an antibody linked to a chemotherapy agent. Accordingly, they have 3 components: an antibody […]

Treatment of Acute Lymphoblastic Leukemia in Older Adults: Now and the Future

Musa Yilmaz, MD, Hagop Kantarjian, MD, and Elias Jabbour, MD

  Abstract: Acute lymphoblastic leukemia (ALL) is an uncommon disease with poor outcomes in older patients. Although intensive chemotherapy can induce complete responses in older patients, […]

Myeloma Bone Disease: Pathogenesis and Treatment

Elizabeth K. O’Donnell, MD, and Noopur S. Raje, MD

  Abstract: Bone involvement manifesting as osteolytic bone disease (OBD) or osteopenia is one of the defining features of multiple myeloma (MM). Osteolytic lesions develop in […]

Advances in the Management of Patients With Carcinoid Syndrome

Clinical Advances in Hematology & Oncology April 2017, Volume 15, Issue 4 Matthew H. Kulke, MD Director, Program in Neuroendocrine and Carcinoid Tumors Senior Physician Dana-Farber […]

Recent Advances in the Management of Gastroenteropancreatic Neuroendocrine Tumors: Insights From the 2017 ASCO Gastrointestinal Cancers Symposium

Clinical Advances in Hematology & Oncology April 2017, Volume 15, Issue 4, Supplement 4 Renuka Iyer, MD, Alexandria T. Phan, MD, and J. Philip Boudreaux, MD, FACS Abstract: […]

View More Issues